KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Equity Average: 2011-2025

Historic Equity Average for Acadia Pharmaceuticals (ACAD) over the last 14 years, with Sep 2025 value amounting to $869.8 million.

  • Acadia Pharmaceuticals' Equity Average rose 59.04% to $869.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.8 million, marking a year-over-year increase of 59.04%. This contributed to the annual value of $582.3 million for FY2024, which is 39.94% up from last year.
  • Acadia Pharmaceuticals' Equity Average amounted to $869.8 million in Q3 2025, which was up 9.58% from $793.8 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Equity Average peaked at $869.8 million during Q3 2025, and registered a low of $379.0 million during Q3 2023.
  • In the last 3 years, Acadia Pharmaceuticals' Equity Average had a median value of $490.4 million in 2024 and averaged $554.7 million.
  • In the last 5 years, Acadia Pharmaceuticals' Equity Average declined by 25.43% in 2022 and then spiked by 67.23% in 2025.
  • Acadia Pharmaceuticals' Equity Average (Quarterly) stood at $553.9 million in 2021, then declined by 25.43% to $413.0 million in 2022, then dropped by 3.89% to $397.0 million in 2023, then surged by 65.00% to $655.0 million in 2024, then spiked by 59.04% to $869.8 million in 2025.
  • Its Equity Average was $869.8 million in Q3 2025, compared to $793.8 million in Q2 2025 and $749.0 million in Q1 2025.